Search Videos and More
News
Dana-Farber Research Points to Potential Gene Therapy Improvements
Viruses aren’t thought of as living beings. Rather, they are collections of genetic instructions that hijack the replication machinery of living cells to perpetuate themselves.
Document
Treatment Guideline: Ovarian Function Suppression and Estradiol Monitoring in Early-Stage Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of ovarian function suppression and estradiol monitoring in early-stage estrogen receptor positive breast cancer.
News
Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally
Cancer can make its way through the body by shapeshifting through even the narrowest places, like a skilled driver navigating traffic. It has a sly way of adapting to its environment by finding detours around every blockade clinicians place in its path.
News
Three Ways Research Could Improve Pancreatic Cancer Treatment
Pancreatic cancer has long been difficult to detect and treat. Dana-Farber experts in the Hale Family Center for Pancreatic Cancer Research, however, are working to change that with research efforts in three key areas that are poised to advance early detection, early intervention, and treatment of the disease.
News
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science
The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations.
News
Pan-Mass Challenge Raises Record $78 Million for Dana-Farber Cancer Institute
The Pan-Mass Challenge (PMC), the world’s single most successful athletic fundraiser, has announced a $78 million gift for cancer research, treatment and patient care at the top-ranked Dana-Farber Cancer Institute.
News
CD123 Targeted Therapies
CD123 is the alpha subunit of the interleukin 3 (IL-3) receptor. It pairs with a beta subunit, CD131, to transmit cytokine signals from the outside to inside of several types of immune and hematopoietic cells. CD123 is highly expressed on the cell surface of several blood cancers.
News
Dana-Farber Research News 11.01.2025
This twice-monthly newsletter highlights recently published research in which Dana-Farber faculty are listed as first or senior authors. The information is sourced from PubMed, and this issue covers papers published October 1-15.
News
A Brighter Future for B-ALL in Adults
Acute lymphoblastic leukemia (ALL) in adults has been historically associated with dismal clinical outcomes. Fortunately, adults diagnosed with ALL are now more likely to experience a favorable response to treatment due to ongoing improvements in immunotherapy.
News
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a cornerstone of curative therapy for patients with high-risk hematologic malignancies.
News
Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3
Venetoclax is an oral selective BCL2 inhibitor, which can restore apoptotic activation in leukemia cells that are dependent on this dysregulated pathway, and in combination with azacitidine (Aza/Ven), is an approved and common frontline therapy for patients with acute myeloid leukemia (AML).
News
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A new and potentially broadly applicable class of anti-leukemic agents has arrived on the scene due to preclinical work done in the laboratory of Scott Armstrong, MD, PhD, of Dana-Farber Cancer Institute in collaboration with members of the Adult Leukemia Program within Medical Oncology at Dana-Farber led by Richard Stone, MD, Chief of Staff.